A previous report regarding the use of another AMP, fungal lysozyme, showed that in an experimental colitis model the presence of gut microbiota was required for the therapeutic effects of the treatment (Larsen et al., 2021), suggesting that the effects of hBD-2 may similarly be microbiota-dependent. The gene discussed is LYZ; the disease is colitis.